Abstract 4142
Background
AntiPD1 Nivolumab (N) or Pembrolizumab (P) are an option for first line treatment in metastatic melanoma (MM) but predictive factors of efficacy are needed to choose between them or other treatment (antiPd1+AntiCTLA4, BRAF+MEK inhibitors (BMEi) for BRAF mutated melanoma). Many studies suggest that LDH, ECOG PS, tumor burden can identify BRAF mutated MM patients (pt) in which BMEi show better outcome. Similar data are not available for N or P in first line. We evaluate pt treated with N or P in first line in order to verify if these factors or other factors can be applyed also to antiPD1.
Methods
A retrospective multicenter study was conducted in 13 Italian Oncology Centers, evaluating MM pt treated with N or P in first line from 2016. Endpoints were OS and PFS, Kaplan Mayer and Cox regression were applied for survival analysis.
Results
236 pt were analyzed (51% treated with N, 7% BRAF mutated). ECOG PS was 0 in 169 pt, number of metastatic sites (Nu) was less then 3 in 135 pt, in 88 pt there were not visceral metastasis (Vi), LDH was normal in 141 pt, ratio between baseline neutrophils and total leukocytes count (Fr) was less then 0.7 in 152 pt: in univariate analysis, all this factors resulted significantly associated with better OS (all p < 0.0003) and PFS (all p < 0.003), the only exeption were pt with Nu less then 3 that resulted not signficantly different in PFS then pt with higher Nu (p 0.13). In multivariate analysis all these factors were confirmed as significantly associated with better PFS and OS (all p < 0.03), with the exeption of Nu (p 0.22) A score was counted for every pt considering the number of favorable baseline factors present (normal LDH, ECOG PS 0, Vi 0, Fr < 0.7) 18 months-PFS was 69% in pt with all 4 favorable factors vs 41% in pt without favorables factors (p value 0.0029). 18 months-OS was 90% in pt with all four favoreble factors vs 48% in pt without favorables factors (p value<0.0001).
Conclusions
ECOG PS 0, normal LDH, Fr < 0.7, absent Vi are indipendent baseline factors associated with favorable PFS and OS of MM pt treated with N or P in first line (instead of Nu – that was found relevant for BMEi in other study). Subgroup with all these factors has a better prognosis. These data can help first line treatment choice and should be evaluated prospectively.
Clinical trial identification
Legal entity responsible for the study
Italian Melanoma Intergroup I.M.I.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
R. Marconcini: Consultancy, Advisory board, Honoraria for speaking: BMS, MSD, Novartis, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1978 - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.
Presenter: Kiyoshi Saeki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3682 - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3319 - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma
Presenter: Min Hee Hong
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5130 - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma
Presenter: Myung-Won Lee
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4483 - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis
Presenter: Thomas Mrowiec
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1175 - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.
Presenter: Naoko Sato
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1359 - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors
Presenter: Miriam López Gómez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2651 - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells
Presenter: Kohei Morita
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2233 - Somatic-stem transition of tumor cells is a key link in the metastasis
Presenter: Nicolai Litviakov
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2601 - Profile of individuals who never undergo colorectal cancer screening
Presenter: Jérôme Viguier
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract